The ratio of the IFN-γ signature to the immunosuppression signature (IMS) better stratifies patients who benefit from treatment with anti-PD-1 antibodies than the expression of several genes demonstrated and validated in melanoma by others [83, 84]. The gene discussed is IFNG; the disease is melanoma.